Drug for anemic cancer patients raises risk of death

CHICAGO -- Millions of cancer patients take drugs to boost their red blood cells and health when they become anemic after chemotherapy. But a new study by Northwestern University's Feinberg School of Medicine shows these drugs, called erythropoiesis-stimulating agents (ESAs), actually raise patients' risk of death, possibly by stimulating the growth of cancer cells.

Adult stem cells may be beneficial for certain cardiovascular disorders and autoimmune diseases

A review of previously published research suggests that stem cells harvested from an adult’s blood or marrow may provide treatment benefit to select patients for some autoimmune diseases and cardiovascular disorders, according to an article in the February 27 issue of JAMA.

Drugs used for cancer-associated anemia linked with increased risk of blood clots, death

Treating anemia with a class of drugs known as erythropoiesis-stimulating agents (ESAs) is associated with an increased risk of venous thromboembolism (blood clots in the deep veins of the legs or in the lungs) and death among patients with cancer, according to an article in the February 27 issue of JAMA.

Switching medications, adding psychotherapy may help teens with ineffective depression medication

For adolescents with depression not responding to an initial treatment with a selective serotonin reuptake inhibitor (SSRI; a class of antidepressant drugs), switching medications and adding cognitive behavioral therapy resulted in an improvement in symptoms, compared to just changing medications, according to a study in the February 27 issue of JAMA.

Teens with treatment-resistant depression more likely to improve with combination therapy

Teens with difficult-to-treat depression who do not respond to a first antidepressant medication are more likely to get well if they switch to another antidepressant medication and add psychotherapy rather than just switching to another antidepressant, according to a large, multi-site trial funded by the National Institutes of Health’s National Institute of Mental Health (NIMH). The results of the Treatment of SSRI-resistant Depression in Adolescents (TORDIA) trial were published February 27, 2008, in the Journal of the American Medical Association (JAMA).

Other highlights in the Feb. 26 JNCI

No Additional Benefit Found for Personalized Intervention to Promote Regular Mammography Screening

Two different interventions did not significantly increase regular mammography screening in a large randomized study.

Behavioral interventions, such as personalized mailings, have been reported to increase one-time cancer screening. However, few studies have examined the impact of behavioral interventions on regular or on-going participation in screening exams.

Breast cancer patients suffer considerable wage losses in first year after diagnosis

Canadian women diagnosed with early breast cancer lose, on average, more than a quarter of their typical income during the first 12 months after their diagnosis, according to a study published online February 26 in the Journal of the National Cancer Institute.

Although a number of studies have assessed the economic impact of breast cancer on the healthcare system, few studies have examined the impact the disease has on the financial status of patients and their families.

New standards needed for radiation therapy

Modern radiation techniques result in substantial variation between the prescribed dose and the actual dose of radiation delivered to the tumor, according to a study published online February 26 in the Journal of the National Cancer Institute. As a result of this newly uncovered trend, the authors are calling for national guidelines for intensity-modulated radiation therapy (IMRT).

Brain stress system presents possible treatment

A brain circuit that underlies feelings of stress and anxiety shows promise as a new therapeutic target for alcoholism, according to new studies by researchers at the National Institute on Alcohol Abuse and Alcoholism (NIAAA), part of the National Institutes of Health (NIH).

Centuries-old Maya Blue mystery finally solved

CHICAGO—Anthropologists from Wheaton College (Illinois) and The Field Museum have discovered how the ancient Maya produced an unusual and widely studied blue pigment that was used in offerings, pottery, murals and other contexts across Mesoamerica from about A.D. 300 to 1500.

First identified in 1931, this blue pigment (known as Maya Blue) has puzzled archaeologists, chemists and material scientists for years because of its unusual chemical stability, composition and persistent color in one of the world’s harshest climates.